Product Description
This compound was initially reported as a gamma -secretase modulator but is now portrayed as acting on multiple targets, particularly microglia. (Sourced from: https://www.alzforum.org/therapeutics/chf-5074)
Mechanisms of Action: G-Secretase Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CERESPIR
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cognitive Dysfunction|Alzheimer Disease|Heart Failure, Chronic
Phase 1: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01258452 |
CT03 | P1 |
Completed |
Alzheimer Disease |
2011-03-01 |
2019-03-19 |
Treatments |
|
NCT01203384 |
CT02 | P1 |
Completed |
Alzheimer Disease |
2010-12-01 |
2019-03-19 |
Treatments |
|
NCT00954252 |
CT01 | P1 |
Completed |
Alzheimer Disease |
2010-05-01 |
2019-03-18 |
Treatments |
|
NCT01723670 |
CT05 | P2 |
Withdrawn |
Alzheimer Disease|Cognitive Dysfunction |
2016-03-01 |
2019-03-19 |
Treatments |
|
NCT01602393 |
CT04 POLEP | P2 |
Completed |
Alzheimer Disease|Cognitive Dysfunction |
2013-10-01 |
2019-06-20 |
Treatments |
|
NCT01421056 |
CT04 OLEP | P2 |
Completed |
Cognitive Dysfunction|Alzheimer Disease |
2012-11-01 |
2019-06-20 |
||
2010-024270-19 |
ND | P2 |
Completed |
Heart Failure, Chronic |
2012-08-08 |
2022-03-13 |
Treatments |
|
NCT01303744 |
CT04 | P2 |
Completed |
Alzheimer Disease |
2012-04-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|